Velimogene aliplasmid

Drug Profile

Velimogene aliplasmid

Alternative Names: Allovectin; Allovectin-7; VCL-1005; VCL-1005-208

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vical
  • Class Antineoplastics; DNA; Gene therapies; Lipids
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Orofacial cancer; Renal cancer

Most Recent Events

  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Belgium (Intratumoural)
  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Brazil (Intratumoural)
  • 12 Aug 2013 Discontinued - Phase-III for Malignant melanoma in Canada (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top